- The NWHN’s statement on the FDA ordering Sprout Pharmaceuticals to retain black box label warning women not mix Addyi and alcohol
April 12, 2019
Contact: Evita Almassi, ealmassi@nwhn.org
Telephone: (202) 682-6240
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.
Washington D.C. — Yesterday the U.S. Food and Drug Administration ordered Sprout Pharmaceuticals to update the label of their female libido pill, flibanserin (brand name: Addyi). The label change says women should ...
- The NWHN’s statement in response to FDA approving Evenity
April 10, 2019
Contact: Evita Almassi, ealmassi@nwhn.org
Telephone: (202) 682-6240
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.
Washington D.C.- Yesterday, the US Food and Drug Administration approved a new treatment romosozumab, brand name Evenity, from drugmakers Amgen and UCB for osteoporosis in postmenopausal women who are at high risk ...
- The NWHN advises women to be cautious about using flibanserin until new studies are fully vetted
March 26, 2019
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.
WASHINGTON D.C. — Women should not use flibanserin or any drug unless they have sufficient information to weigh benefits against risks. Sprout Pharmaceuticals’ new alcohol studies should be reviewed with a healthy skepticism, until they have been vetted ...
- NWHN statement in response to the FDA’s action against Aid Access
March 12, 2019
Contact: Evita Almassi, ealmassi@nwhn.org
Telephone: (202) 682-6240
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.
Washington D.C.- In a letter released Tuesday, the FDA warned online abortion pill provider AidAccess.org to immediately stop importing mifepristone and misoprostol, the two drugs that make up the most ...
- The NWHN’s statement on the resignation of FDA Commissioner Scott Gottlieb
March 5, 2019
Contact: Evita Almassi, ealmassi@nwhn.org
Telephone: (202) 682-6240
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.
Washington D.C.- Today, US Food and Drug Administration Commissioner Scott Gottlieb announced his plan to leave the FDA in about a month.
Prior to his confirmation, the NWHN raised concerns about Gottlieb’s approach to women’s health, his close ties to the pharmaceutical industry, and ...
- The NWHN’s Statement on Title X Rule Release
February 22, 2019
For Immediate Release
Contact: Evita Almassi, ealmassi@nwhn.org
The following statement can be attributed to Sarah Christopherson, Policy Advocacy Director at the National Women’s Health Network
Washington, D.C. – Today, the Trump-Pence administration is once again attacking women’s reproductive health. Last year, HHS rushed through a proposed rule to gut Title X, the country’s only domestic family planning grant ...
- NWHN Statement on FDA’s decision on Generic Drug Labels
December 13, 2018
For Immediate Release
Contact: Evita Almassi, ealmassi@nwhn.org
Telephone: (202) 682-6240
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.
Washington, DC — Today the U.S. Food and Drug Administration (FDA) announced their decision to withdraw the proposed rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological ...
- NWHN calls for Kavanaugh to withdraw nomination
September 24, 2018
For Immediate Release
Contact: Evita Almassi, ealmassi@nwhn.org
Telephone: (202) 682-2640
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.
Washington, DC — Yesterday, a second accuser bravely came forward with disturbing allegations of sexual assault by Supreme Court nominee, Brett Kavanaugh. Today, news reports suggest that there may be ...
- NWHN Statement on Christine Blasey Ford Speaking Out On Kavanaugh Sexual Assault Allegations
September 17, 2018
For Immediate ReleaseContact: Evita Almassi, ealmassi@nwhn.org Telephone: (202) 682-2640
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.
In light of very credible allegations of sexual assault against Judge Brett Kavanaugh, the Senate Judiciary Committee must postpone their vote until a fair, thorough, and nonpartisan investigation has ...
- The FDA has decided not to approve the Uterine Fibroid drug, Esyma
August 22, 2018
For Immediate Release
Contact: Cynthia Pearson, cpearson@nwhn.org
Telephone: (202) 682-2640, x222
The following statement can be attributed to Cynthia A. Pearson, Executive Director of the National Women’s Health Network.
Washington, D.C. — Esmya, a drug intended to treat uterine fibroids, was turned down by the U.S. Food and Drug Administration in a decision announced by Allergan, the U.S. ...
